Hyris
27.9.2023 14:06:04 CEST | ACCESS Newswire | Press release
Following the launch of its Marketplace in 2022, Hyris continues to leverage the AI capabilities of its genetic testing platform, renowned for its adaptability, to support both researchers and kit developers worldwide. New onboarding programs enable emerging players to accelerate their go-to-market, as well as established manufacturers and diagnostic providers to integrate their portfolio with ease, maximizing their cost-per-value strategy.
LONDON, UK / ACCESSWIRE / September 27, 2023 / In the age of early mass dissemination of accessible AI solutions, many specialists and researchers from different scientific, technical and academic fields claim that AI has not yet gone far enough. According to a recent Editorial published in Nature, several research fields which need accurate and accessible data won't achieve their full potential until they integrate adequate machine-learning systems.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.With Hyris both established and emerging test developers can optimize their go-to-market by leveraging the power of AI.
Even if AI tools promise a disruption in the way researchers seek and synthesize useful new substances and tests, we are far from a wholesale revolution yet, also because of the lack of data available to feed centralized AI systems. This poses several challenges to researchers and kit developers in designing and delivering new testing solutions.
Hyris keeps true to its vision, to democratize genetics and health insights, marking a new stage in its partnership policies with newfangled onboarding programs specifically designed to further support researchers and kit developers at every stage.
"Genetic test developing and onboarding has always been faced with inherent challenges, from resource staffing to competence integration, from research funding to ensuring adequate testing volumes," states Angelica Baccanelli, Head of Quality & Regulation at Hyris. "Adapting to variability in the compliance environment, applying requirements to molecular assays, and developing the proper documentation for the go-to-market can all pose additional risks."
Amongst many challenges, technological access gaps are still the greatest hindrance to the development of new solutions across different industries. Hyris stands to change this for the better, by leveraging the AI capabilities of its unique genetic testing platform, renowned worldwide for its AI capabilities together with its unique features of portability, accessibility and versatility.
"Researchers and kit developers know well how hard delivering new analytical solutions can be," continues Baccanelli. "That's why we increased our commitment to support both emerging players and established manufacturers performing beyond their current analytical capability via new onboarding programs." Baccanelli goes on, depicting the advantages of such an inclusive approach. "We provide access to our technology and support developers through various stages of the development of new tests via proper education and technical assistance. This win-win approach enables any player to quickly integrate their portfolio with new products and solutions, maximizing their cost per value strategy."
Hyris's Onboarding strategy is proving successful across many industries. Such is the case of Luminis, Water Technologies, a leader in microbiome profiling and treatment solutions, which embraced Hyris' Program to bring on-site qPCR diagnostics to the aquaculture industry, enabling customers to quickly and accurately test for pathogens, viruses, and bacteria, ultimately improving their operations' overall safety and productivity in such industry. Luminis adopted the Hyris system to develop new qPCR diagnostics kits, enabling its customers to perform genetic analysis on-site rather than sending samples to a lab, significantly reducing turnaround time and allowing for more informed decision-making. Additionally, on-site testing eliminates the need for expensive lab equipment, and operators can now perform testing with minimal training.
"The benefits of on-site qPCR diagnostics are numerous," explains Lorenzo Colombo, CTO at Hyris, "ensuring faster turnaround time and reduced costs, compared to centralized diagnostic systems. On the other hand, the downsides of such an approach have been the lack of accuracy and the complexity of on-site technologies, making this approach less suitable for day-to-day operations until now. We fixed all these problems, providing highly accurate results whilst requiring minimal training to operate. Hyris can really be used in any setting, even under the harshest conditions."
Hyris' distributed technology allows the identification of new and arising needs, even from decentralized areas: this, in turn, enables the design and deployment of fitting solutions at a very early stage of any diagnostic trend, throughout various diverse use cases. Kit developers and lab specialists can now truly collaborate, tapping into different levels of data analysis in real-time to bring innovative tests with superior quality and increased fitness to market; dressing on the cake, all the more quickly and efficiently.
"Too often, centralized diagnostic paradigms risk overlooking local needs, preventing benefits from being shared equitably," sums up Stefano Lo Priore, co-founder and CEO at Hyris. "This also poses an ethical question, as innovations often fail to benefit those who need them most. Reliable portable diagnostic systems are key to building new capabilities for established and emerging diagnostic service providers. By helping others to deliver their solutions, we also fulfil our mission, generating a much wider impact worldwide."
The new Onboarding Programs are contributing to making Hyris the first choice for testing labs, test developers, and researchers looking to bring on specific tests involving smaller sample arrays, reduced time to results, and increased efficiencies and profitability.
To discover how to perform beyond your current diagnostic capability, feel free to contact a Hyris expert at info@hyris.net.
Contact Information
Gabriele Salaris
Global Experience Manager
gabriele.salaris@hyris.net
+39 345 555 3379
SOURCE: Hyris
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/787258/hyris-supports-researchers-and-developers-to-launch-testing-kits-via-new-onboarding-programs
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi Announces Second Quarter 2026 Earnings Release and Call Date20.7.2026 22:30:00 CEST | Press release
Fermi to host earnings call on August 13, 2026 DALLAS, TX / ACCESS Newswire / July 20, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it plans to release second quarter 2026 financial results at 7 a.m. Eastern Time / 12 p.m. British Time on Thursday, August 13, 2026. This announcement will be followed by an earnings conference call at 9 a.m. Eastern Time / 2 p.m. British Time. The Company's earnings release and supplemental information will be posted to the Investors section of the Company's website prior to the conference call. To join the live conference call, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally approximately 15 minutes prior to the scheduled start time and refer to conference code 587288. The call will also be webcast in a listen-only mode and can be accessed through the Investor Relations Events & Presentations page of Fermi's website. A replay of the webcast will be available for
GA-ASI and KONGSBERG Advance JSM Integration for MQ-9B20.7.2026 12:05:00 CEST | Press release
Companies Bring Joint Strike Missile Weapon System to Leading Uncrewed Platform SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and KONGSBERG Gruppen ASA (KONGSBERG) completed the System Requirements Review (SRR) and Preliminary Design Review (PDR) for the integration of the Joint Strike Missile (JSM) weapon system onto MQ-9B. This design and integration effort is a jointly funded project by both companies aimed at providing long-range strike capability for MQ-9B and its customers. These reviews were successfully completed in Kongsberg, Norway, on June 30. MQ-9B is an industry-leading uncrewed aircraft system (UAS) manufactured by GA-ASI and includes the SkyGuardian® and SeaGuardian® models. KONGSBERG produces the JSM, a best-in-class weapon system for use against high-priority targets. "We recognize the value JSM brings to our MQ-9B platform," said Niki Johnson, GA-ASI Vice President, International Capture and Government Affairs. "
GA-ASI Completes Qualification Testing for UK Protector Weapons20.7.2026 12:00:00 CEST | Press release
Concludes 6-Year U.S. and U.K. Governmental and Industry Collaboration SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has completed weapons testing for the Royal Air Force's (RAF) Protector RG Mk1 Remotely Piloted Aircraft, qualifying both the Paveway IV laser-guided bomb and the Brimstone 3 air-to-surface missile for launch from GA-ASI's MQ-9B aircraft. Testing was completed on June 18 at GA-ASI's facilities in Southern California and marked the first time that GA-ASI has taken the lead role in completing weapons qualification for a customer. The qualification testing was conducted under UK Ministry of Defence approval and met all requirements for certification of the safe carriage and release of weapons. "The Royal Air Force is our MQ-9B launch customer and we're here to support them in any way we can," said GA-ASI President David R. Alexander. "Leading the qualification test was a unique experience and we're excited to complete
ePropelled to Showcase Next Generation Electric Propulsion, Software Innovation and Autonomous Systems Capabilities at Farnborough International Airshow 202617.7.2026 17:00:00 CEST | Press release
Meet the ePropelled team in Hall 2, Stand 2039, on the New Hampshire Mission Pavilion FARNBOROUGH, UK / ACCESS Newswire / July 17, 2026 / ePropelled, a leading global provider of smart propulsion solutions and energy management systems, will exhibit at the Farnborough International Airshow 2026, showcasing its latest innovations for aerospace, defense and uncrewed vehicle applications. Visitors to Hall 2, Stand 2039 on the New Hampshire Mission Pavilion will have the opportunity to meet the ePropelled team and learn about a range of exciting developments, including new product launches, software innovations, technology updates and exclusive previews of next-generation solutions currently in development. With autonomy, electrification and intelligent mobility driving the future of aerospace and defence, ePropelled continues to develop advanced propulsion, power management and software technologies that enhance performance, efficiency and mission capability across air, land and maritime
As the UK Backs Life Sciences and Advanced Manufacturing, US PMO Firm MustardSeed Moves In to Help Deliver It16.7.2026 11:00:00 CEST | Press release
The expansion reflects growing client demand for embedded programme management support across highly regulated industries. WEST CHESTER, PA AND MANCHESTER, UK / ACCESS Newswire / July 16, 2026 / The UK Government's 2025 Modern Industrial Strategy has put life sciences, advanced manufacturing, defence, and clean energy at the centre of Britain's growth agenda. MustardSeed, a US-based programme management and PMO consultancy, is launching UK operations to help organisations in those sectors deliver on that ambition. The 2025 Modern Industrial Strategy names life sciences and advanced manufacturing among its eight priority sectors, alongside defence and clean energy. These are industries defined by complex, regulated, multi-stakeholder programmes where disciplined execution directly determines commercial and operational outcomes. MustardSeed, headquartered in West Chester, Pennsylvania, has built its practice around delivering that execution. The firm announced today the launch of its UK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
